期刊
MOLECULAR GENETICS AND METABOLISM
卷 87, 期 4, 页码 303-310出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2005.10.021
关键词
clinical proteomics; cystic fibrosis; antibody microarray; Reverse Capture Protein Microarray
资金
- NHLBI NIH HHS [N01-HV 28187] Funding Source: Medline
- NIDDK NIH HHS [R01-DK53051] Funding Source: Medline
Antibody microarrays are a new proteomic technology, which we have developed as a platform for identifying a cystic fibrosis (CF)specific serum proteomic signature. Serum samples from CF patients have been pooled and compared with equivalent pools of control sera in order to identify patterns of protein expression unique to CF. We find that the set of significantly differentially expressed proteins is enriched in protein mediators of inflammation from the NF kappa B signaling pathway, and in proteins that may be selectively expressed in CF-affected tissues such as lung and intestine. In several instances, we validate the data from the antibody microarrays by quantitative analysis with Reverse Capture Protein Microarrays. We conclude that antibody microarray technology is sensitive, quantitative, and robust, and can be useful as a proteomic platform to discriminate between sera from CF and control patients. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据